News | Cath Lab | December 27, 2018

Study Finds Effective Treatment for Coronary Slow Flow

Researchers find effective way to treat underdiagnosed condition that can cause heart attack and heart-attack-like symptoms.

Study Finds Effective Treatment for Coronary Slow Flow

December 27, 2018 — Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if scans came back clear, with no signs of blocked coronary arteries. Some of these cases are caused by a little-known phenomenon called coronary slow flow. Now, researchers at Jefferson (Philadelphia University + Thomas Jefferson University), have demonstrated for the first time a simple technique to effectively treat this under-recognized condition. They published their findings in the Journal of Invasive Cardiology on Dec. 15.1

“One of the biggest issues with coronary slow flow is that many cardiologists aren’t familiar with it and don’t know what to look for to diagnose it,” said senior author Michael Savage, M.D., director of the cardiac catheterization lab at the Sidney Kimmel Medical College at Thomas Jefferson University. “Here we’ve shown that once you do recognize it, the condition can be treated with an existing and safe medical intervention that reverses the problem.”

Not a lot is known about the coronary slow flow. It is identified by angiogram of the heart, revealing arteries that fill with blood more slowly than normal, even in the absence of fatty plaque deposits. But what causes the condition, and why in 80 percent of cases patients experience additional episodes of chest pain, is still unknown. One association that can be drawn, said first author Hetal H. Mehta, M.D., a cardiology fellow at Jefferson, is that smokers are two-to-three times more likely to experience the phenomenon.

When Savage and others first saw the condition on angiograms of their patients, it appeared similar to the no-reflow phenomenon caused by microvascular spasm during coronary angioplasty procedures. Since that condition could be treated with a drug called nicardipine, Savage and colleagues decided to test it with their coronary slow flow patients. “It worked incredibly well,” he said.

In this study, the researchers analyzed the data and outcomes of 30 patients with coronary slow flow who were treated during cardiac catheterization with an intracoronary injection of nicardipine. They found a total of 49 blood vessels with slow blood flow. After treatment with nicardipine, all of the vessels showed normalized blood flow.

“These results suggest that microvascular spasm may be responsible for this condition, which can be effectively reversed with a calcium channel blocker like nicardipine,” said Savage. “It’s a simple intervention that takes only a few seconds to administer, and helps diagnose the condition and treat it at the same time.”

Nicardipine appears to reverse the condition in the short term, but future studies are needed to explore whether the one-time treatment reverses the condition permanently, or whether patients would benefit from long-term use of an oral calcium channel blocker.

The authors report no conflicts of interest.

For more information: www.invasivecardiology.com

Reference

1. Mehta H.H., Morris M., Fischman D.L., et al. The Spontaneous Coronary Slow-Flow Phenomenon: Reversal by Intracoronary Nicardipine. Journal of Invasive Cardiology, Dec. 15, 2018.


Related Content

News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
Home
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
Home
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
Home
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
Home
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
Home
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
Home
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
Home
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Home
Subscribe Now